Your browser doesn't support javascript.
loading
Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas.
Zhao, Sibo; Li, Jia; Zhang, Huiyuan; Qi, Lin; Du, Yuchen; Kogiso, Mari; Braun, Frank K; Xiao, Sophie; Huang, Yulun; Li, Jianfang; Teo, Wan-Yee; Lindsay, Holly; Baxter, Patricia; Su, Jack M F; Adesina, Adekunle; Laczik, Miklós; Genevini, Paola; Veillard, Anne-Clemence; Schvartzman, Sol; Berguet, Geoffrey; Ding, Shi-Rong; Du, Liping; Stephan, Clifford; Yang, Jianhua; Davies, Peter J A; Lu, Xinyan; Chintagumpala, Murali; Parsons, Donald William; Perlaky, Laszlo; Xia, Yun-Fei; Man, Tsz-Kwong; Huang, Yun; Sun, Deqiang; Li, Xiao-Nan.
Afiliação
  • Zhao S; Pre-clinical Neuro-oncology Research Program, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Li J; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Zhang H; Jane and John Justin Neurosciences Center, Cook Children's Medical Center, Fort Worth, TX, 76104, USA.
  • Qi L; Hematology and Oncology Center, Cook Children's Medical Center, Fort Worth, TX, 76104, USA.
  • Du Y; Center for Epigenetics & Disease Prevention, Texas A&M University, Houston, TX, 77030, USA.
  • Kogiso M; Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, 77030, USA.
  • Braun FK; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University; and Guangzhou Laboratory, Bioland, 510120, Guangzhou, Guangdong, P. R. China.
  • Xiao S; Pre-clinical Neuro-oncology Research Program, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Huang Y; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Li J; Pre-clinical Neuro-oncology Research Program, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Teo WY; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Lindsay H; Program of Precision Medicine PDOX Modeling of Pediatric Tumors, Division of Hematology-Oncology, Neuro-Oncology & Stem Cell transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, 6061
  • Baxter P; Pre-clinical Neuro-oncology Research Program, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Su JMF; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Adesina A; Program of Precision Medicine PDOX Modeling of Pediatric Tumors, Division of Hematology-Oncology, Neuro-Oncology & Stem Cell transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, 6061
  • Laczik M; Pre-clinical Neuro-oncology Research Program, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Genevini P; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Veillard AC; Pre-clinical Neuro-oncology Research Program, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Schvartzman S; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Berguet G; Program of Precision Medicine PDOX Modeling of Pediatric Tumors, Division of Hematology-Oncology, Neuro-Oncology & Stem Cell transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, 6061
  • Ding SR; Pre-clinical Neuro-oncology Research Program, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Du L; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Stephan C; Department of Neurosurgery and Brain and Nerve Research Laboratory, the First Affiliated Hospital, and Department of Neurosurgery, Dushu Lake Hospital, Suzhou Medical College, Soochow University, 215007, Suzhou, P. R. China.
  • Yang J; Center for Epigenetics & Disease Prevention, Texas A&M University, Houston, TX, 77030, USA.
  • Davies PJA; Humphrey Oei Institute of Cancer Research, National Cancer Center Singapore, Singapore, 169610, Singapore.
  • Lu X; Cancer and Stem Cell Biology Program, Duke-NUS Medical School Singapore, Singapore, Singapore.
  • Chintagumpala M; KK Women's & Children's Hospital Singapore, Singapore, Singapore.
  • Parsons DW; Institute of Molecular and Cell Biology, A*STAR, Singapore, Singapore.
  • Perlaky L; Pre-clinical Neuro-oncology Research Program, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Xia YF; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Man TK; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Huang Y; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Sun D; Department of Pathology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Li XN; Epigenetic Services, Diagenode, Liège, Belgium.
Nat Commun ; 13(1): 6689, 2022 11 05.
Article em En | MEDLINE | ID: mdl-36335125
ABSTRACT
Recurrence is frequent in pediatric ependymoma (EPN). Our longitudinal integrated analysis of 30 patient-matched repeated relapses (3.67 ± 1.76 times) over 13 years (5.8 ± 3.8) reveals stable molecular subtypes (RELA and PFA) and convergent DNA methylation reprogramming during serial relapses accompanied by increased orthotopic patient derived xenograft (PDX) (13/27) formation in the late recurrences. A set of differentially methylated CpGs (DMCs) and DNA methylation regions (DMRs) are found to persist in primary and relapse tumors (potential driver DMCs) and are acquired exclusively in the relapses (potential booster DMCs). Integrating with RNAseq reveals differentially expressed genes regulated by potential driver DMRs (CACNA1H, SLC12A7, RARA in RELA and HSPB8, GMPR, ITGB4 in PFA) and potential booster DMRs (PLEKHG1 in RELA and NOTCH, EPHA2, SUFU, FOXJ1 in PFA tumors). DMCs predicators of relapse are also identified in the primary tumors. This study provides a high-resolution epigenetic roadmap of serial EPN relapses and 13 orthotopic PDX models to facilitate biological and preclinical studies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Simportadores / Ependimoma Limite: Child / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Simportadores / Ependimoma Limite: Child / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
...